Reference
Dewilde S, et al. Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective. Cost Effectiveness and Resource Allocation : No. 18, 10 Feb 2020. Available from: URL: https://doi.org/10.1186/s12962-020-0205-4
Rights and permissions
About this article
Cite this article
Dexrazoxane cost effective in preventing anthracycline cardiotoxicity. Reactions Weekly 1791, 8 (2020). https://doi.org/10.1007/s40278-020-74853-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-74853-5